about
The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosisEvidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report.Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.A case of life-threatening post-operative diffuse alveolar hemorrhage in patient with recent chemotherapy -A case report-.Delayed Paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer.Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report.Drug-associated acute lung injury: a population-based cohort study.Thin-Section CT Characteristics and Longitudinal CT Follow-up of Chemotherapy Induced Interstitial Pneumonitis: A Retrospective Cohort Study.Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort studyQuercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKCε-dependent activation of TRPV1.Progressive multiple cystic changes in both lungs in a patient treated with gefitinib for lung adenocarcinoma with multiple lung metastases.Pulmonary toxicities from targeted therapies: a review.Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors.Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports.Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.[Pulmonary complications in chemotherapy].Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
P2860
Q21559629-3AA58B01-1DA1-477C-BE4C-BEBF8094CDF7Q26752747-57159CF3-64CF-4672-A3C5-4462C58CE0A3Q30540860-98D91200-983E-417F-9574-8C8A126536A8Q33426732-9739EF2F-731C-4521-B40D-734A1885E251Q33519052-971D9686-BAC7-4AA2-8C8A-3ED2B9024C48Q34472111-F6495C27-31A2-485F-A1D1-F331BC022E57Q34626688-A3057CCE-E3B3-44F8-B7F0-184AAAAB5417Q34765803-E9A1782D-0D34-4C49-B71C-D817A3698BB4Q34832259-DF7A8476-256B-45AD-8079-6076619C8421Q35060147-65F62560-4484-4AF0-A203-09A526B4522FQ36300143-04779433-9692-4B71-BA5B-C1CB846801CDQ36478155-0F6F3627-1827-452E-9C39-462A89FCA17BQ36696444-881DDED6-35BD-44F9-8F9C-E662993F041EQ37254578-AFF48541-D4D9-4259-BC4C-C75CD145E312Q37640172-E1F53A83-7C92-4D29-9165-08EEA8A03540Q37955066-EF576104-8B9A-4C3B-8E54-305234797E09Q38060727-DA000B4C-2887-4931-96E4-5D03B8AD80F7Q38220276-6DE49B70-DB89-41FB-81FC-3B33AD876A5EQ39474553-D82C0E01-26C5-462C-8411-6B425524F114Q39980036-01A11EDB-765A-4DE4-981E-BF2E6CB7B937Q41139723-92865B07-06E2-4DA6-AB48-947E77E5E715Q41701062-57395330-E91F-4470-A0EB-5A489A0BB99AQ48857119-5E002941-C4ED-48F7-BB0A-2A21584AEBDC
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pulmonary toxicity from novel antineoplastic agents.
@ast
Pulmonary toxicity from novel antineoplastic agents.
@en
type
label
Pulmonary toxicity from novel antineoplastic agents.
@ast
Pulmonary toxicity from novel antineoplastic agents.
@en
prefLabel
Pulmonary toxicity from novel antineoplastic agents.
@ast
Pulmonary toxicity from novel antineoplastic agents.
@en
P2093
P2860
P356
P1433
P1476
Pulmonary toxicity from novel antineoplastic agents.
@en
P2093
I Dimopoulou
P Lyberopoulos
P2860
P304
P356
10.1093/ANNONC/MDJ057
P577
2005-11-16T00:00:00Z